129 related articles for article (PubMed ID: 38157645)
1. Programmed Co-delivery of tamoxifen and docetaxel using lipid-coated mesoporous silica nanoparticles for overcoming CYP3A4-mediated resistance in triple-negative breast cancer treatment.
Wang Y; Cheng W; Zhu J; He L; Ren W; Bao D; Piao JG
Biomed Pharmacother; 2024 Jan; 170():116084. PubMed ID: 38157645
[TBL] [Abstract][Full Text] [Related]
2. Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma.
Hsu TI; Chen YP; Zhang RL; Chen ZA; Wu CH; Chang WC; Mou CY; Chan HW; Wu SH
ACS Appl Mater Interfaces; 2024 May; 16(17):21722-21735. PubMed ID: 38629735
[TBL] [Abstract][Full Text] [Related]
3. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel.
Wang D; Huang J; Wang X; Yu Y; Zhang H; Chen Y; Liu J; Sun Z; Zou H; Sun D; Zhou G; Zhang G; Lu Y; Zhong Y
Biomaterials; 2013 Oct; 34(31):7662-73. PubMed ID: 23859657
[TBL] [Abstract][Full Text] [Related]
4. The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles.
Zhu Z; Li Y; Yang X; Pan W; Pan H
Pharmacol Res; 2017 Dec; 126():84-96. PubMed ID: 28734999
[TBL] [Abstract][Full Text] [Related]
5. Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer.
Patel K; Chowdhury N; Doddapaneni R; Boakye CHA; Godugu C; Singh M
J Pharm Sci; 2015 Dec; 104(12):4417-4426. PubMed ID: 26372815
[TBL] [Abstract][Full Text] [Related]
6. Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer.
He C; Cai P; Li J; Zhang T; Lin L; Abbasi AZ; Henderson JT; Rauth AM; Wu XY
J Control Release; 2017 Jan; 246():98-109. PubMed ID: 28017889
[TBL] [Abstract][Full Text] [Related]
7. Improved Antitumor Efficacy of a Dextran-based Docetaxel-coupled Conjugate against Triple-Negative Breast Cancer.
Lv H; Jia W; Dong P; Liu J; Wang S; Li X; Hu J; Zhao L; Shi Y
Curr Drug Deliv; 2024; 21(5):775-784. PubMed ID: 37349996
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of micellar-like terpolymer nanoparticles with reductively-cleavable cross-links and evaluation of efficacy in 2D and 3D models of triple negative breast cancer.
Monteiro PF; Gulfam M; Monteiro CJ; Travanut A; Abelha TF; Pearce AK; Jerôme C; Grabowska AM; Clarke PA; Collins HM; Heery DM; Gershkovich P; Alexander C
J Control Release; 2020 Jul; 323():549-564. PubMed ID: 32371266
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of Docetaxel and Disulfonate Tetraphenyl Chlorin in One Nanoparticle Produces Strong Synergism between Chemo- and Photodynamic Therapy in Drug-Sensitive and -Resistant Cancer Cells.
Gaio E; Conte C; Esposito D; Miotto G; Quaglia F; Moret F; Reddi E
Mol Pharm; 2018 Oct; 15(10):4599-4611. PubMed ID: 30148955
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of PEGylated biodegradable nanoparticles for sustained release of docetaxel in triple-negative breast cancer.
Palma G; Conte C; Barbieri A; Bimonte S; Luciano A; Rea D; Ungaro F; Tirino P; Quaglia F; Arra C
Int J Pharm; 2014 Oct; 473(1-2):55-63. PubMed ID: 24992317
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Synergism Mechanism of Tamoxifen and Docetaxel by Nanoparticles.
Zhu Z; Pan H; Li Y; Pan W
Anticancer Agents Med Chem; 2019; 19(16):1991-2000. PubMed ID: 31267877
[TBL] [Abstract][Full Text] [Related]
12. Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy.
Fan Y; Wang Q; Lin G; Shi Y; Gu Z; Ding T
Acta Biomater; 2017 Oct; 62():257-272. PubMed ID: 28859899
[TBL] [Abstract][Full Text] [Related]
13. Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer.
Doddapaneni R; Patel K; Chowdhury N; Singh M
Exp Cell Res; 2016 Aug; 346(1):65-73. PubMed ID: 27177833
[TBL] [Abstract][Full Text] [Related]
14. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
[TBL] [Abstract][Full Text] [Related]
15. Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles.
Chen R; Ni S; Chen W; Liu M; Feng J; Hu K
Int J Nanomedicine; 2021; 16():5265-5279. PubMed ID: 34376979
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer.
Paiva KLR; Radicchi MA; Báo SN
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956870
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticles with Optimal Ratiometric Co-Delivery of Docetaxel with Gambogic Acid for Treatment of Multidrug-Resistant Breast Cancer.
Xu Y; Wang C; Ding Y; Wang Y; Liu K; Tian Y; Gao M; Li Z; Zhang J; Li L
J Biomed Nanotechnol; 2016 Sep; 12(9):1774-81. PubMed ID: 29345888
[TBL] [Abstract][Full Text] [Related]
18. Efficient in vitro and in vivo docetaxel delivery mediated by pH-sensitive LPHNPs for effective breast cancer therapy.
Jadon RS; Sharma G; Garg NK; Tandel N; Gajbhiye KR; Salve R; Gajbhiye V; Sharma U; Katare OP; Sharma M; Tyagi RK
Colloids Surf B Biointerfaces; 2021 Jul; 203():111760. PubMed ID: 33872827
[TBL] [Abstract][Full Text] [Related]
19. Angiopep-2 modified lipid-coated mesoporous silica nanoparticles for glioma targeting therapy overcoming BBB.
Zhu J; Zhang Y; Chen X; Zhang Y; Zhang K; Zheng H; Wei Y; Zheng H; Zhu J; Wu F; Piao JG; Zhu Z; Li F
Biochem Biophys Res Commun; 2021 Jan; 534():902-907. PubMed ID: 33162028
[TBL] [Abstract][Full Text] [Related]
20. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
